PI3K inhibitor add-on strategy improve glucocorticoid insensitivity in severe asthma

Z. Chen (Shanghai, China), J. Bi (Shanghai, China), Z. Min (Shanghai, China), C. Du (Shanghai, China)

Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms
Session: Asthma science: novel targets and mechanisms
Session type: E-poster session
Number: 2906
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Z. Chen (Shanghai, China), J. Bi (Shanghai, China), Z. Min (Shanghai, China), C. Du (Shanghai, China). PI3K inhibitor add-on strategy improve glucocorticoid insensitivity in severe asthma. 2906

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
JAK inhibitors overcome corticosteroid insensitivity in COPD
Source: Annual Congress 2011 - COPD: clinical studies and animal cell models
Year: 2011

Corticosteroids: use and insensitivity in severe asthma
Source: Eur Respir Mon 2011; 51: 236-252
Year: 2011

RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems
Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Year: 2013

Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 21s
Year: 2004

RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation
Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017
Year: 2017

Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003

Oxidative stress-induced corticosteroid insensitivity is reversed by formoterol via inhibition of PI3K signalling in peripheral blood mononuclear cells from patients with COPD and severe asthma
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011

Specific NFKappaB and Rho-Quinase inhibitors compared to corticosteroid in asthma model in mice
Source: International Congress 2017 – Translational studies of lung disease
Year: 2017

GRC39815-A novel inhaled ROR?t inhibitor as a potential first in class treatment option for COPD
Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies
Year: 2021

The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003

Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation
Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018
Year: 2019

Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 303s
Year: 2002

Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD
Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights
Year: 2019

Inhaled JAK inhibitor GDC-4379 reduces FeNO in patients with mild asthma
Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence
Year: 2021

Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations
Source: Eur Respir J 2016; 47: 783-791
Year: 2016

Protein phosphatase PP2A activation by formoterol reverses corticosteroid insensitivity
Source: Annual Congress 2009 - Airway cell biology
Year: 2009

The way to improve the steroid sensitivity of target cells of patients with severe therapy resistant asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 313s
Year: 2006

An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD
Source: Eur Respir J, 52 (5) 1801675; 10.1183/13993003.01675-2018
Year: 2018

Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019